Arcturus Therapeutics Holdings Inc. (ARCT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ARCT SEC filings page.
Arcturus Therapeutics Holdings Inc. (ARCT) reported $29.4M in revenue over the twelve months to Jun 30, 2026, down 76.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business remains R&D-heavy and cash-consuming: falling revenue has not reduced development needs, despite 37.3 months of reported liquidity.
From FY2024 to FY2025, revenue fell46.1% while R&D fell42.5% , meaning development spending contracted less than sales. Operating cash outflow of$74M nearly matched free cash flow of-$75M , showing that cash consumption came mainly from ongoing operations rather than capital investment.
R&D was
Liabilities were
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Arcturus Therapeutics Holdings Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Arcturus Therapeutics Holdings Inc. held $230.9M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $74.3M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Arcturus Therapeutics Holdings Inc. scores 61/100 among other emerging companies.
Arcturus Therapeutics Holdings Inc. had 28M shares outstanding at the end of fiscal year 2025, against 27M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Arcturus Therapeutics Holdings Inc. scores 62/100 among other emerging companies.
Arcturus Therapeutics Holdings Inc. spent $112.2M on research and development in fiscal year 2025, which was 70.9% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Arcturus Therapeutics Holdings Inc. scores 92/100 among other emerging companies.
Arcturus Therapeutics Holdings Inc. reported revenue of $82.0M in fiscal year 2025, against $152.3M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Arcturus Therapeutics Holdings Inc. scores 13/100 among other emerging companies.
Arcturus Therapeutics Holdings Inc.'s operations used $74.3M of cash in fiscal year 2025, against $59.7M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Arcturus Therapeutics Holdings Inc. scores 8/100 among other emerging companies.
Arcturus Therapeutics Holdings Inc.'s cash, cash equivalents and investments came to $230.9M at the end of fiscal year 2025, against $57.2M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Arcturus Therapeutics Holdings Inc. scores 86/100 among other emerging companies.
Arcturus Therapeutics Holdings Inc. scores 1.21, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($341.9M) relative to total liabilities ($57.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Arcturus Therapeutics Holdings Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Arcturus Therapeutics Holdings Inc. reported a net loss of $65.8M while operations used $74.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Arcturus Therapeutics Holdings Inc. generated $3.0M in revenue in Q2 2026. This represents a decrease of 89.5% from the same quarter a year earlier. Against the prior quarter it is up 43.6%.
Arcturus Therapeutics Holdings Inc.'s EBITDA was -$24.9M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 130.6% from the same quarter a year earlier. Against the prior quarter it is up 11.8%.
Arcturus Therapeutics Holdings Inc. reported -$23.8M in net income in Q2 2026. This represents a decrease of 159.1% from the same quarter a year earlier. Against the prior quarter it is up 11.8%.
Arcturus Therapeutics Holdings Inc. earned -$0.84 per diluted share (EPS) in Q2 2026. This represents a decrease of 147.1% from the same quarter a year earlier. Against the prior quarter it is up 11.6%.
Cash & Balance Sheet
Arcturus Therapeutics Holdings Inc. recorded an outflow of $19.9M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 246.0% from the same quarter a year earlier. Against the prior quarter it is down 2.4%.
Arcturus Therapeutics Holdings Inc. held $191.5M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Arcturus Therapeutics Holdings Inc.'s ROE was -13.8% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 9.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.3 percentage points.
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Arcturus Therapeutics Holdings Inc. invested $17.5M in research and development in Q2 2026. This represents a decrease of 40.8% from the same quarter a year earlier. Against the prior quarter it is down 18.6%.
Arcturus Therapeutics Holdings Inc. reported no capital expenditure in Q2 2026.
Not reported for Q2 2026.
ARCT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0M-89.5% | $2.1M-93.0% | $7.2M-68.4% | $17.2M-58.8% | $28.3M-43.2% | $29.4M-22.7% | $22.8M-26.2% | $41.7M-7.7% |
| R&D Expenses | $17.5M-40.8% | $21.5M-38.3% | $24.5M-44.1% | $23.3M-40.6% | $29.6M-49.6% | $34.9M-34.9% | $43.8M+19.6% | $39.1M-23.4% |
| SG&A Expenses | $11.0M+6.3% | $9.5M-16.3% | $14.0M+13.3% | $10.4M-21.7% | $10.3M-16.1% | $11.3M-23.8% | $12.4M-1.0% | $13.3M-0.8% |
| Operating Income | -$25.5M-119.9% | -$28.9M-71.9% | -$31.3M+6.3% | -$16.5M-53.8% | -$11.6M+45.0% | -$16.8M+44.7% | -$33.4M-82.8% | -$10.7M+44.4% |
| EBITDA | -$24.9M-130.6% | -$28.3M-76.4% | -$30.7M+5.8% | -$15.7M-59.7% | -$10.8M+46.5% | -$16.0M+45.7% | -$32.6M-87.2% | -$9.8M+46.9% |
| Income Tax | $0-100.0% | N/A | N/A | N/A | $4K+102.7% | $0-100.0% | -$5K-101.9% | -$217K-124.3% |
| Net Income | -$23.8M-159.1% | -$27.0M-91.6% | -$29.1M+3.1% | -$13.4M-94.8% | -$9.2M+46.7% | -$14.1M+47.5% | -$30.0M-156.3% | -$6.9M+57.4% |
| EPS (Basic) | -$0.84-147.1% | -$0.95-82.7% | -$1.05+5.4% | -$0.49-88.5% | -$0.34+46.9% | -$0.52+48.0% | -$1.11-152.3% | -$0.26+57.4% |
| EPS (Diluted) | -$0.84-147.1% | -$0.95-82.7% | -$1.05+5.4% | -$0.49-88.5% | -$0.34+46.9% | -$0.52+48.0% | -$1.11-152.3% | -$0.26+57.4% |
| Diluted Shares (Avg) | 28M+4.8% | 28M+4.8% | N/A | 27M+0.5% | 27M+0.6% | 27M+0.8% | N/A | 27M+1.8% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
ARCT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $224.3M-27.5% | $245.4M-26.0% | $271.1M-21.2% | $282.3M-23.8% | $309.3M-20.4% | $331.8M-20.8% | $344.1M-19.9% | $370.7M-19.0% |
| Current Assets | $197.2M-28.2% | $216.9M-22.2% | $241.4M-21.1% | $249.2M-24.7% | $274.5M-20.9% | $278.8M-25.8% | $306.0M-20.9% | $330.8M-15.9% |
| Cash & Equivalents | $191.5M-2.5% | $211.4M-2.6% | $230.9M-2.6% | $180.4M-24.0% | $196.5M-24.5% | $216.9M-24.8% | $237.0M-18.8% | $237.2M-24.0% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Receivable | $1.8M-89.5% | $1.3M-90.8% | $5.6M+40.0% | $8.0M-73.7% | $17.2M-28.6% | $14.6M-46.1% | $4.0M-87.6% | $30.2M-21.0% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $52.5M-32.9% | $54.0M-44.9% | $57.2M-44.6% | $57.8M-46.9% | $78.2M-39.8% | $98.0M-36.7% | $103.1M-31.7% | $108.8M-38.7% |
| Current Liabilities | $33.5M-27.9% | $34.4M-30.4% | $36.4M-44.5% | $31.7M-54.4% | $46.5M-49.3% | $49.4M-57.2% | $65.5M-20.1% | $69.5M-20.8% |
| Non-Current Liabilities | $19.0M-40.2% | $19.7M-59.5% | $20.8M-44.7% | $26.1M-33.7% | $31.7M-17.2% | $48.6M+23.2% | $37.6M-45.4% | $39.3M-56.3% |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | $15.0M | N/A | N/A |
| Total Equity | $171.8M-25.6% | $191.4M-18.1% | $214.0M-11.2% | $224.6M-14.2% | $231.1M-10.6% | $233.8M-11.4% | $241.0M-13.5% | $261.9M-6.5% |
| Retained Earnings | -$565.3M-19.8% | -$541.6M-17.0% | -$514.6M-14.7% | -$485.5M-15.9% | -$472.1M-14.6% | -$462.9M-17.3% | -$448.8M-22.0% | -$418.8M-17.6% |
Not reported in any period shown, so not listed: Inventory, Goodwill.
ARCT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$19.9M-246.0% | -$19.4M+44.7% | -$16.2M-5613.7% | -$17.2M+27.8% | -$5.8M+80.9% | -$35.1M-532.3% | -$284K+54.8% | -$23.8M+26.7% |
| Depreciation & Amortization | $600K-25.0% | $658K-17.9% | $682K-16.7% | $800K-11.1% | $800K-11.1% | $801K-11.4% | $819K+0.5% | $900K+12.5% |
| Stock-Based Compensation | $4.2M-31.8% | $4.3M-35.1% | N/A | $5.7M-39.7% | $6.2M-34.2% | $6.7M-34.0% | N/A | $9.5M+2.4% |
| Capital Expenditures | $0 | $0-100.0% | -$88K | $181K+126.3% | $0-100.0% | $137K-42.9% | $0-100.0% | $80K-91.8% |
| Free Cash Flow | -$19.9M-246.0% | -$19.4M+44.9% | -$16.3M-5644.7% | -$17.3M+27.3% | -$5.8M+81.1% | -$35.3M-508.5% | -$284K+81.1% | -$23.8M+28.6% |
| Investing Cash Flow | $18K | $34K+124.8% | $88K | -$181K-126.3% | $0+100.0% | -$137K+42.9% | $0+100.0% | -$80K+91.8% |
| Financing Cash Flow | $0+100.0% | $16K-99.9% | $11.7M+8622.4% | $1.2M+76.8% | -$14.7M-712.8% | $15.2M+594.5% | $134K+100.7% | $693K-96.8% |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 |
Not reported in any period shown, so not listed: Share Buybacks.
ARCT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -863.3% | -1403.7% | -435.0% | -96.3%-70.5pp | -41.0%+1.3pp | -57.3%+22.7pp | -146.7% | -25.8%+17.0pp |
| Net Margin | -803.8% | -1308.3% | -404.0% | -78.4%-61.9pp | -32.4%+2.1pp | -47.9%+22.6pp | -131.8% | -16.6%+19.4pp |
| Return on Equity | -13.8%-9.9pp | -14.1%-8.1pp | -13.6%-1.1pp | -6.0%-3.4pp | -4.0%+2.7pp | -6.0%+4.1pp | -12.5%-8.2pp | -2.6%+3.1pp |
| Return on Assets | -10.6%-7.6pp | -11.0%-6.8pp | -10.7%-2.0pp | -4.8%-2.9pp | -3.0%+1.5pp | -4.2%+2.2pp | -8.7%-6.0pp | -1.9%+1.7pp |
| Current Ratio | 5.880.0x | 6.31+0.7x | 6.64+2.0x | 7.86+3.1x | 5.90+2.1x | 5.64+2.4x | 4.670.0x | 4.76+0.3x |
| Debt-to-Equity | 0.310.0x | 0.28+0.2x | 0.27-0.2x | 0.26-0.2x | 0.34-0.2x | 0.06-0.5x | 0.43-0.1x | 0.42+0.3x |
| Asset Turnover | 0.01-0.1x | 0.01-0.1x | 0.030.0x | 0.06-0.1x | 0.090.0x | 0.090.0x | 0.070.0x | 0.110.0x |
| FCF Margin | -672.9% | -943.3% | -226.7% | -101.1% | -20.3%+40.8pp | -120.1% | -1.3%+3.6pp | -57.2%+16.7pp |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. ARCT | FY2025 | $82.0M | -$65.8M | -80.2% | $341.9M | 54/100 |
| aTyr Pharma, Inc. ATYR | FY2025 | $190K | -$74.1M | N/A | $19.7M | — |
| REGENXBIO Inc. RGNX | FY2025 | $170.4M | -$193.9M | N/A | $479.3M | 64/100 |
| Opthea Limited American OPT | FY2025 | $25K | -$162.8M | N/A | $524.8M | — |
| Bicycle Therapeutics plc BCYC | FY2025 | $72.6M | -$219.0M | N/A | $254.1M | 60/100 |
Where Arcturus Therapeutics Holdings Inc. Ranks
Frequently Asked Questions
What is Arcturus Therapeutics Holdings Inc.'s annual revenue?
Arcturus Therapeutics Holdings Inc. (ARCT) reported $82.0M in total revenue for fiscal year 2025. This represents a -46.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Arcturus Therapeutics Holdings Inc.'s revenue growing?
Arcturus Therapeutics Holdings Inc. (ARCT) revenue declined by 46.1% year-over-year, from $152.3M to $82.0M in fiscal year 2025.
Is Arcturus Therapeutics Holdings Inc. profitable?
No, Arcturus Therapeutics Holdings Inc. (ARCT) reported a net income of -$65.8M in fiscal year 2025, with a net profit margin of -80.2%.
What is Arcturus Therapeutics Holdings Inc.'s EBITDA?
Arcturus Therapeutics Holdings Inc. (ARCT) had EBITDA of -$73.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Arcturus Therapeutics Holdings Inc.'s operating margin?
Arcturus Therapeutics Holdings Inc. (ARCT) had an operating margin of -93.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Arcturus Therapeutics Holdings Inc.'s net profit margin?
Arcturus Therapeutics Holdings Inc. (ARCT) had a net profit margin of -80.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Arcturus Therapeutics Holdings Inc.'s return on equity (ROE)?
Arcturus Therapeutics Holdings Inc. (ARCT) has a return on equity of -30.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Arcturus Therapeutics Holdings Inc.'s free cash flow?
Arcturus Therapeutics Holdings Inc. (ARCT) recorded an outflow of $74.5M in free cash flow during fiscal year 2025. This represents a -23.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Arcturus Therapeutics Holdings Inc.'s operating cash flow?
Arcturus Therapeutics Holdings Inc. (ARCT) recorded an outflow of $74.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Arcturus Therapeutics Holdings Inc.'s total assets?
Arcturus Therapeutics Holdings Inc. (ARCT) had $271.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Arcturus Therapeutics Holdings Inc.'s capital expenditures?
Arcturus Therapeutics Holdings Inc. (ARCT) invested $230K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Arcturus Therapeutics Holdings Inc. spend on research and development?
Arcturus Therapeutics Holdings Inc. (ARCT) invested $112.2M in research and development during fiscal year 2025.
What is Arcturus Therapeutics Holdings Inc.'s current ratio?
Arcturus Therapeutics Holdings Inc. (ARCT) had a current ratio of 6.64 as of fiscal year 2025, which is generally considered healthy.
What is Arcturus Therapeutics Holdings Inc.'s debt-to-equity ratio?
Arcturus Therapeutics Holdings Inc. (ARCT) had a debt-to-equity ratio of 0.27 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Arcturus Therapeutics Holdings Inc.'s return on assets (ROA)?
Arcturus Therapeutics Holdings Inc. (ARCT) had a return on assets of -24.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Arcturus Therapeutics Holdings Inc.'s P/E ratio?
Arcturus Therapeutics Holdings Inc. (ARCT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $341.9M as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Arcturus Therapeutics Holdings Inc.'s price-to-sales ratio?
Arcturus Therapeutics Holdings Inc. (ARCT) trades at 11.6x sales, its market capitalization divided by revenue of $29.4M revenue, trailing 12 months to June 30, 2026. The market capitalization is $341.9M as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Arcturus Therapeutics Holdings Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Arcturus Therapeutics Holdings Inc. (ARCT) held $230.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $74.3M over that year. Dividing the one by the other, the reported balance equals about 37 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Arcturus Therapeutics Holdings Inc.'s Altman Z-Score?
Arcturus Therapeutics Holdings Inc. (ARCT) has an Altman Z-Score of 1.21, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Arcturus Therapeutics Holdings Inc.'s Piotroski F-Score?
Arcturus Therapeutics Holdings Inc. (ARCT) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Arcturus Therapeutics Holdings Inc.'s earnings high quality?
Arcturus Therapeutics Holdings Inc. (ARCT) reported a net loss of $65.8M while operations used $74.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Arcturus Therapeutics Holdings Inc.?
Arcturus Therapeutics Holdings Inc. (ARCT) scores 54 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.